More patients are arriving at clinics, pre-op assessments and emergency departments with something on their medication list that did not come from a pharmacy. Often it is a peptide: a GLP-1 compound bought online for weight loss, BPC-157 for an injury, or a blend recommended by a coach. These products are usually sold as “research use only” and arrive as freeze-dried powder that the patient mixes and injects at home.

Nurses are often the first to hear about them, which puts nursing in a strong position to spot risks early. That does not require expert knowledge of every compound. It requires knowing what to ask, what to look out for, and a basic understanding of third-party peptide testing so you can judge how much is known about what the patient is actually injecting.

Why patients use them

Patients tend to fall into a few groups. Some are seeking weight loss and could not get, or afford, a prescription GLP-1 medicine. Some are athletes or gym users looking for faster recovery or muscle gain. Others are interested in skin, sleep, hair or general “anti-aging” claims they have seen on social media.

Most research peptides are not approved for human use in the US, the UK, Canada or Australia, and the sellers are not regulated like pharmacies. Patients are not always aware of this. Many assume that a professional-looking website and a lab certificate mean a product is effectively the same as a medicine.

Asking the question

Patients are more likely to disclose when the question is routine and neutral. Adding a line to the medication history works well: “Do you take anything you bought online or outside a pharmacy, including peptides, injections or anything from a gym or coach?”

If the answer is yes, reassure the patient that the purpose is safety, not judgment. A patient who feels criticized may leave out the details that matter most.

What to document

Once a patient discloses a self-sourced peptide, try to record:

• The product name, exactly as written on the vial, and whether it is a single compound or a blend.
• The source, such as a website, a compounding pharmacy, a gym or a friend.
• How it is prepared. Ask what liquid they mix it with. Bacteriostatic water, sterile water and saline are all used, and some patients use tap water or other unsuitable diluents.
• How it is given, including route, site, needle type and whether anything is reused.
• Dose and frequency, and how they measure it. Many patients draw up doses using insulin syringe units, and conversion errors between units and milligrams are common.
• Storage. Most reconstituted peptides should be refrigerated. Vials kept at room temperature for long periods may have degraded.
• Duration of use and any symptoms they have noticed.

A photo of the vial label on the patient’s phone can be helpful for the prescriber or pharmacist.

Risks to look out for

Injection-related complications. Products made outside regulated conditions may not be sterile. Watch for redness, swelling, warmth or abscess at injection sites, and ask about technique if these appear.

Allergic and hypersensitivity reactions. Peptides and impurities from synthesis can trigger reactions ranging from local itching to more serious systemic responses.

GLP-1 specific risks. Self-sourced semaglutide, tirzepatide or retatrutide can cause the gastrointestinal effects seen with approved GLP-1 medicines: nausea, vomiting, constipation and dehydration. Combined with insulin or sulfonylureas, they increase the risk of hypoglycemia. Severe abdominal pain should prompt consideration of pancreatitis or gallbladder disease. Dosing errors have led to hospital admissions, according to adverse event reports collected by the FDA.

Peri-operative risk. GLP-1 compounds slow gastric emptying. Current anesthesia guidance asks teams to consider this before procedures because of aspiration risk. A patient using an online product may not think to mention it, so ask specifically during pre-op assessment.

Sport and occupation. Several peptides, including BPC-157, are prohibited in tested sport. Patients in competitive sport or professions with drug testing may not realize this.

What a lab report can and cannot tell you

Patients sometimes show a certificate of analysis from the seller as evidence that a product is safe. It helps to understand what such a report means.

A good certificate comes from an independent laboratory, names the sample and batch, and includes at least two results: purity by HPLC and identity by mass spectrometry. Identity confirms that the vial contains the named molecule. Purity describes how much of the detectable material is that molecule. Better reports also include endotoxin testing, which is particularly relevant for anything injected.

Even a strong report has limits. It describes one sample from one batch. It does not confirm that the patient’s vial came from that batch unless the numbers match, and it says nothing about storage after testing. It is not a sterility guarantee unless sterility was tested, and it is never an approval for human use.

Reports printed on the seller’s own letterhead, reports without batch numbers, and identical results reused across many products are all reasons for caution.

Escalate and report

Share the information with the prescriber and pharmacist, particularly where there are possible interactions or the patient is going for a procedure. Where an adverse event occurs, report it through the appropriate system, such as FDA MedWatch in the US or the Yellow Card scheme in the UK. Reports on unregulated products help regulators see patterns they would otherwise miss.

A nursing opportunity

Self-sourced peptides are unlikely to disappear. Nurses who ask about them routinely, document them carefully and explain their risks calmly can catch problems that would otherwise go unnoticed until something goes wrong. That makes a single extra question in the medication history one of the more valuable minutes in an assessment.

Stay updated, free articles. Join our Telegram channel

Join